Evaluating JAB-21822 for pancreatic cancer and other solid tumors with a specific mutation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II trial is a single-arm, multicenter, open-label study that focuses on adult patients with locally advanced or metastatic solid tumors harboring the KRAS p.G12C mutation. It includes patients with advanced pancreatic cancer who have progressed after or are intolerant to prior gemcitabine-based chemotherapy or FOLFIRINOX treatments, as well as those with other solid tumors who lack satisfactory alternative therapies. The primary aim is to assess the efficacy and safety of the drug Glecirasib in these populations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with the KRAS p.G12C mutation confirmed through testing using prospectively validated companion diagnostic reagents or clinical trial assay (CTA) methods.
* Histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumors (excluding NSCLC and CRC).
* Patients with pancreatic cancer must have progressed or been intolerant to prior gemcitabine-based chemotherapy regimens or FOLFIRINOX/mFOLFIRINOX/NALIRIFOX treatment. Patients with other types of solid tumors must have progressed or been intolerant to prior systemic therapies and lack satisfactory alternative treatment options.

Exclusion Criteria:

* Previously received a KRAS G12C inhibitor.
* History of interstitial lung disease, non-infectious pneumonia, or uncontrolled lung disease (including pulmonary fibrosis, acute lung disease, etc.) with clinical symptoms.
* Uncontrolled pleural effusion, pericardial effusion, or ascites.
* Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 electrocardiograms.
* Use of a drug with known risk of torsades de points (TdP) within 14 days prior to the first dose.

Where it's running

• Anhui Provincial Cancer Hospital
  Hefei, Anhui, China Recruiting
• Beijing Cancer Hospital
  Beijing, Beijing Municipality, China Recruiting
• Peking Union Medical College Hospital
  Beijing, Beijing Municipality, China Recruiting
• Beijing Tsinghua Changgung Hospital
  Beijing, Beijing Municipality, China Recruiting
• Cancer Hospital Chinese Academy of Medical Sciences
  Beijing, Beijing Municipality, China Recruiting
• Fujian Cancer Hospital
  Fuzhou, Fujian, China Recruiting

Study contacts

• Study coordinator: Shanghai Allist Pharmaceuticals Co., Ltd
• Email: zhenhua.gong@allist.com.cn
• Phone: 86-21-80423288

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PT0511 for advanced solid tumors with KRAS mutations or amplifications

  This trial tests whether the drug PT0511, given alone or with cetuximab for colorectal cancer, is safe and tolerable in adults with advanced solid tumors that have KRAS mutations or KRAS amplification.

  Recruiting at 9 sites Phase 1 PAQ Therapeutics, Inc. · Boston, Massachusetts and 8 other locations · NCT07300150

• Using brodalumab to treat immune-related side effects from cancer therapy

  This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06673329

• Evaluating BL-M17D1 for HER2 Positive Gastrointestinal Cancer

  This study is testing a new drug called BL-M17D1 to see if it is safe and effective for people with advanced HER2 positive gastrointestinal cancer and other solid tumors.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT06500052

• Evaluating AGX101 for advanced solid tumors

  This study is testing a new drug called AGX101 to see if it can help people with advanced solid tumors who haven't had success with other treatments.

  Recruiting at 7 sites Phase 1 Angiex, Inc. · Los Angeles, California and 6 other locations · NCT06440005

• Testing QLC1101 for advanced solid tumors with KRAS G12D mutation

  This study is testing a new drug called QLC1101 to see if it can help people with advanced solid tumors that have a specific KRAS G12D mutation, especially those who haven't had success with other treatments.

  Recruiting Phase 1 Qilu Pharmaceutical Co., Ltd. · Guangzhou, Guangdong and 4 other locations · NCT06403735

• Testing AST-001 in patients with advanced solid tumors

  This study is testing a new treatment called AST-001 to see if it is safe and effective for people with advanced solid tumors, like pancreatic cancer.

  Recruiting Phase 1/2 Ascentawits Pharmaceuticals, Ltd · Changchun, Jinlin · NCT06245330

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.